HAEMONETICS CORP - Director's Dealing 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-06-06

Reporting Person: Simon, Christopher (Director, President & CEO)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-06	Common Stock	M	104516	$41.64	Acquired	433877	Direct
2024-06-06	Common Stock	F	71335	$87.38	Disposed	362542	Direct

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-06	Non-qualified Stock Option (Right to Buy)	$41.64	M	104516	Disposed	2024-06-06	Common Stock (104516)	Direct

F1: Represents an automatic exercise of options granted in 2017 and scheduled to expire after June 6, 2024, as reflected in this Form 4.

F2: This number includes unvested restricted stock units previously reported.

F3: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.